Literature DB >> 10991992

Discovery of "self-synergistic" spinal/supraspinal antinociception produced by acetaminophen (paracetamol).

R B Raffa1, D J Stone, R J Tallarida.   

Abstract

The mechanism of the analgesic action of one of the world's most widely used drugs-acetaminophen (paracetamol)-remains largely unknown more than 100 years after its original synthesis. Based on the present findings, this elusiveness appears to have resulted from experimental strategies that concentrated on a single target site or mechanism. Here we report on the use of analyses that we previously developed to investigate possible brain/spinal-cord site-site interaction in acetaminophen-induced antinociception. Spinal (intrathecal) administration of acetaminophen to mice produced dose-related, naloxone-insensitive antinociception with an ED(50) value of 137 (S.E. = 23) microgram = 907 (S.E. =153) nmol. In contrast, supraspinal (i.c.v.) acetaminophen administration had no effect. However, combined administration of acetaminophen in fixed ratios to brain and spinal cord produced synergistic antinociception, ED(50) = 57 (S.E. = 9) microgram, that reverted toward additivity, ED(50) = 129 (S.E. = 23) microgram, when the opioid antagonist naloxone was given spinally (3.6 microgram = 10 nmol) or s.c. (3.6 mg/kg). These findings demonstrate for the first time that acetaminophen-induced antinociception involves a "self-synergistic" interaction between spinal and supraspinal sites and, furthermore, that the self-synergy involves an endogenous opioid pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991992

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

Review 1.  [Non-opioid analgesics for perioperative pain therapy. Risks and rational basis for use].

Authors:  A Brack; H L Rittner; M Schäfer
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

Review 2.  The determination and application of fixed-dose analgesic combinations for treating multimodal pain.

Authors:  Robert B Raffa; Joseph V Pergolizzi; Ronald J Tallarida
Journal:  J Pain       Date:  2010-03-24       Impact factor: 5.820

Review 3.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

4.  TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol.

Authors:  David A Andersson; Clive Gentry; Lisa Alenmyr; Dan Killander; Simon E Lewis; Anders Andersson; Bernard Bucher; Jean-Luc Galzi; Olov Sterner; Stuart Bevan; Edward D Högestätt; Peter M Zygmunt
Journal:  Nat Commun       Date:  2011-11-22       Impact factor: 14.919

Review 5.  The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations.

Authors:  Ronald J Tallarida; Robert B Raffa
Journal:  Pharmacol Ther       Date:  2010-05-28       Impact factor: 12.310

6.  Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Authors:  R B Raffa; R J Tallarida
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

Review 7.  Pharmacological aspects of successful long-term analgesia.

Authors:  Robert Raffa
Journal:  Clin Rheumatol       Date:  2006-06-02       Impact factor: 2.980

Review 8.  Pain management today - what have we learned?

Authors:  Richard M Langford
Journal:  Clin Rheumatol       Date:  2006-06-02       Impact factor: 2.980

9.  Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.

Authors:  Nieves Vélez de Mendizábal; Dalia Vásquez-Bahena; Juan M Jiménez-Andrade; Mario I Ortiz; Gilberto Castañeda-Hernández; Iñaki F Trocóniz
Journal:  AAPS J       Date:  2012-09-12       Impact factor: 4.009

10.  Drug Combinations: Tests and Analysis with Isoboles.

Authors:  Ronald J Tallarida
Journal:  Curr Protoc Pharmacol       Date:  2016-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.